On August 28, DUALITYBIO-B rose 5.27% in regular trading, trading at 204.0 HKD/share, with turnover of approximately 28.91 million HKD. The rally was driven by the announcement of a global research, development, collaboration, and licensing agreement with Genentech, a Roche Group member company.

Under the agreement, the two parties will co-develop next-generation antibody-drug conjugates (ADCs) based on DUALITYBIO-B's proprietary DUPAC novel payload platform targeting multiple tumor indications. DUALITYBIO-B will lead discovery and early-stage global clinical development, with Genentech obtaining global exclusive licensing rights upon Phase 1a completion and assuming responsibility for subsequent development and commercialization. The company will receive a $45 million upfront payment. The DUPAC platform encompasses payloads including DUP5, DUP9, and DUP10, each with distinct anti-tumor mechanisms.

Additionally, the company is scheduled to disclose interim results after today's close. UBS recently initiated coverage with a Buy rating and a target price of 320 HKD, implying significant upside from current levels.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)